Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This is a Phase II study of the investigational drug opaganib. Patients with metastatic
castration resistant prostate cancer (mCRPC) who have experienced disease progression while
receiving abiraterone or enzalutamide will receive Opaganib at either 250 mg or 500 mg by
mouth twice a day continuously. Patients will continue on study drug until the development of
progressive disease, intolerable toxicity, withdrawal of patient consent or other event as
outlined in patient discontinuation.